Tasly Pharmaceutical Group Co., Ltd (SHA: 600535)

Tasly Pharmaceutical Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	4,460	4,451	3,119	2,304	1,976	1,891
Trading Asset Securities	1,336	300.71	1,125	1,487	142.92	59.39
Cash & Short-Term Investments	5,796	4,751	4,244	3,791	2,119	1,950
Cash Growth	42.83%	11.95%	11.95%	78.94%	8.63%	-37.83%
Accounts Receivable	2,019	2,131	3,348	3,796	5,198	11,138
Other Receivables	17.86	11.49	8.98	9.47	421.43	208.63
Receivables	2,037	2,142	3,357	3,805	5,619	11,347
Inventory	1,816	1,748	1,532	1,548	1,354	2,547
Other Current Assets	109.85	91.43	127.08	105	145.92	699.16
Total Current Assets	9,758	8,733	9,260	9,249	9,237	16,543
Property, Plant & Equipment	3,672	3,769	3,883	4,088	3,881	4,011
Long-Term Investments	1,942	2,054	1,511	1,229	1,535	1,209
Goodwill	15.88	15.88	15.88	167.08	15.88	143.24
Other Intangible Assets	548.05	573.64	459.43	474.54	361.4	408.71
Long-Term Deferred Tax Assets	47.46	50	88.29	60.79	42.82	119.92
Long-Term Deferred Charges	1,570	1,476	1,157	1,193	1,412	1,579
Other Long-Term Assets	49.9	43.14	102.08	79.68	8.45	0.45
Total Assets	17,604	16,714	16,477	16,542	16,494	24,014
Accounts Payable	1,549	497.12	757.15	603.79	572.52	2,747
Accrued Expenses	134.41	178.72	242.79	213.15	200.28	230.25
Short-Term Debt	856.42	814.63	201.77	188.79	638.73	2,719
Current Portion of Long-Term Debt	440.65	462.39	475.21	343.33	1,137	2,207
Current Portion of Leases	56.17	58.54	53.98	55.67	-	-
Current Income Taxes Payable	14.79	18.04	84.62	108.09	34.6	86.02
Current Unearned Revenue	103.15	91.62	92.35	68.33	26.82	-
Other Current Liabilities	149.38	248.49	239.34	273.91	221.86	668.39
Total Current Liabilities	3,304	2,370	2,147	1,855	2,832	8,657
Long-Term Debt	1,238	1,414	1,376	1,034	1,020	3,233
Long-Term Leases	64.63	81.52	75.31	81.63	-	-
Long-Term Unearned Revenue	154.96	159.02	177.79	214.57	234.56	256.18
Long-Term Deferred Tax Liabilities	0.11	0.11	22.87	42.18	22.55	3.98
Total Liabilities	4,761	4,024	3,799	3,228	4,109	12,150
Common Stock	1,494	1,500	1,500	1,513	1,513	1,513
Additional Paid-In Capital	863.56	958.08	1,457	1,530	2,321	1,991
Retained Earnings	10,098	9,929	9,351	10,222	8,359	7,730
Treasury Stock	-	-105.98	-105.98	-251.29	-194.86	-100.09
Comprensive Income & Other	75.65	88	211.58	-32.19	-25.1	-1.89
Total Common Equity	12,531	12,368	12,412	12,981	11,972	11,132
Minority Interest	311.9	321.59	265.12	332.56	411.77	732.19
Shareholders' Equity	12,843	12,690	12,678	13,314	12,384	11,864
Total Liabilities & Equity	17,604	16,714	16,477	16,542	16,494	24,014
Total Debt	2,656	2,831	2,182	1,704	2,796	8,158
Net Cash (Debt)	3,140	1,920	2,062	2,088	-677.47	-6,208
Net Cash Growth	304.92%	-6.87%	-1.23%	-	-	-
Net Cash Per Share	2.11	1.29	1.40	1.39	-0.45	-4.09
Filing Date Shares Outstanding	1,494	1,494	1,494	1,499	1,503	1,508
Total Common Shares Outstanding	1,494	1,494	1,494	1,499	1,503	1,508
Working Capital	6,455	6,363	7,113	7,394	6,406	7,886
Book Value Per Share	8.39	8.28	8.31	8.66	7.97	7.38
Tangible Book Value	11,967	11,779	11,937	12,340	11,595	10,580
Tangible Book Value Per Share	8.01	7.88	7.99	8.23	7.71	7.02
Buildings	3,500	3,505	3,490	3,398	3,239	3,115
Machinery	3,667	3,625	3,472	3,340	2,974	2,821
Construction In Progress	197.44	153.87	102.96	167.85	400.97	614.02

Source: S&P Capital IQ. Standard template. Financial Sources.